OTLC

Oncotelic Therapeutics, Inc.

OTC· Pharmaceutical Preparations· Inc. DE· CIK 0000908259 Biotech & Drug Discovery

$0.0157 −0.00 (−21.50%)

Oct 26 4:00 PM ET · prev $0.0200

Next earnings

Nov 16

in 21 days

1 year

−84.3%

from $0.1000 · Oct 27

30 days

−47.7%

from $0.0300

52-week range

$0.0157–0.1100

at the low

Avg volume 20D

399.1K

Oct 1 spike 1.38M

Short interest

15.9K

+20.8%

Days to cover

1.0

at average volume

Insider net

+$37.8K

2 buyers · 0 sellers · 12 mo

Filing reports

analyzed by SecBot

SecBot read MIXED 2 reports · 90 days

Balance 0 bearish · 0 bullish · 2 neutral oldest → newest, height = score

Avg score

·High conf. 1/2 ·Next Earnings date, Nov 16, 2026

Strongest NEUTRAL Oncotelic Therapeutics filed an 8-K to report presentations at Drug Discovery 2026 regarding its PDAOAI…

All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

R Apr 16 Oncotelic Therapeutics reported a $249 million net income for FY 202…
B Jun 15 to Jul 1 6 days of insider buys: $37.8K by 2 insiders, avg $0.0445
R Jun 29 Oncotelic Therapeutics entered into a securities purchase agreement…
X Jul 15 Short interest falls 38.3% to 58.5K
X Jul 31 Short interest falls 83.7% to 9.6K
X Aug 14 Short interest falls 99.8% to 16
X Aug 31 Short interest jumps 100000.0% to 27.6K
X Sep 15 Short interest falls 52.5% to 13.1K

Signal stack

Where each data set points today.

InsidersBULLISH

2 insiders bought $37.8K at an average $0.0445. No open-market sales. Price is 65% below their cost.
Short sellersBUILDING

Short interest +20.8% to 15.9K shares. 1.0 days to cover.
TrendDOWNTREND

41% below its 50-day average. New closing low $0.0157 on Oct 26.

Recent activity

The latest filings, insider trades, analyst actions, press and options flow — newest first.

Oct 26, 2026 SEC

🔒 Fresh report (last 24h), subscribers only

Oct 13, 2026 SEC

Oncotelic Therapeutics filed an 8-K to report presentations at Drug Discovery 2026 regarding its PDAOAI platform and…

8-K — Impact 2/10

Aug 11, 2026 Earnings calendar

OTLC Q2 2026 Earnings Scheduled — 2026-08-11

Jul 14, 2026 SEC

Oncotelic Therapeutics filed an 8-K attaching a corporate presentation (Exhibit 99.1) and a Restricted Stock Unit…

8-K — Impact 2/10

Jul 10, 2026 Insider

Saund Saran was granted 1,500 shares

CBO

Jul 10, 2026 Insider

MAIDA ANTHONY E III was granted 1,500 shares

DIRECTOR AND CMO - TRANS. MED.

Jul 10, 2026 Insider

Shah Amit B. was granted 1,500 shares

CFO

Insider ledger

Form 4

$37.8K

bought · 2 insiders

sold · 0 insiders

−64.7%

vs their $0.0445 cost

Date	Insider	Type	Value
Jul 10, 2026	Saund Saran CBO	AWARD	1,500 sh
Jul 10, 2026	MAIDA ANTHONY E III DIRECTOR AND CMO - TRANS. MED.	AWARD	1,500 sh
Jul 10, 2026	Shah Amit B. CFO	AWARD	1,500 sh
Jul 10, 2026	Trieu Vuong CHAIRMAN AND CEO	AWARD	2,000 sh
Jul 10, 2026	KING STEVEN W Director	AWARD	250 sh
Jul 10, 2026	Fein Seymour Howard CRO/CMO	AWARD	250 sh
Jul 1, 2026	Trieu Vuong CHAIRMAN AND CEO	BUY	$10.3K
Jun 24, 2026	Trieu Vuong CHAIRMAN AND CEO	BUY	$5.2K